Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Statins not protective against dengue in infected patients with hyperlipidaemia

Jairia Dela Cruz
29 Nov 2018

Statins appear to confer no benefit for dengue severity in patients with hyperlipidaemia, according to a Singapore study.

Specifically, use of the lipid-lowering medication upon hospital admission does not reduce dengue severity in infected hyperlipidaemia patients, the investigators said. “However, prior use of statins is not a risk factor for increased liver inflammation and supports the safety of continuing statins in patients with dengue.”

The study population included 257 dengue patients (mean age 61.3 years; 51.0 percent female) with a history of hyperlipidaemia, among whom 191 (74.3 percent) were statin users and 66 (25.7 percent) were nonusers. Medications used included simvastatin (69.1 percent), lovastatin (17.3 percent), atorvastatin (8.4 percent), rosuvastatin (4.2 percent) and pravastatin (1.0 percent).

Compared with nonusers, statin users were significantly more likely to be overweight or obese, have a history of hypertension and chronic liver disease. Moreover, users were more likely to develop tachycardia and fluid accumulation and severe plasma leakage.

Multivariate Poisson regression analysis showed no association between statin use and reduced risk of both dengue haemorrhagic fever/shock syndrome (adjusted risk ratio [aRR], 0.66; 95 percent CI, 0.41–1.08; p=0.10) and severe dengue (aRR, 1.43; 0.84–2.43; p=0.19). [Sci Rep 2018;8:17147]

The risk estimates indicate that statin usage has minimal effect on dengue severity in the study population in Singapore, the investigators pointed out.

Despite the presence of several limitations, the present data “suggest that discontinuation of statins may not be necessary at the onset of dengue infection, and clinicians may adopt a watchful approach of continuing statins,” they added.

While discontinuation of statins may not be harmless even for short periods of time, an abrupt withdrawal has been shown to lead to impaired endothelial function via nitric oxide release and higher C-reactive protein levels, resulting in a proinflammatory state. [J Pharmacol Exp Ther 2011;339:324-328]

“With an ageing population compounded by a rise in obesity and associated comorbidities in Singapore, it is not uncommon that patients can present with dengue on a background of multiple medical problems that may pose a therapeutic challenge,” they said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.